Rallybio (NASDAQ:RLYB) Stock Price Up 5.1% – Still a Buy?

Shares of Rallybio Corporation (NASDAQ:RLYB) traded up 5.1% on Monday . The company traded as high as $0.7799 and last traded at $0.7693. 173,094 shares traded hands during trading, an increase of 1% from the average session volume of 170,709 shares. The stock had previously closed at $0.7320.

Analyst Ratings Changes

RLYB has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a research note on Monday, December 8th. Wall Street Zen downgraded Rallybio from a “hold” rating to a “sell” rating in a research report on Sunday, October 12th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Rallybio has an average rating of “Reduce” and a consensus target price of $5.00.

Rallybio Trading Up 5.1%

The business has a 50-day moving average price of $0.63 and a 200-day moving average price of $0.53. The stock has a market cap of $32.50 million, a PE ratio of -2.40 and a beta of -1.04.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. Rallybio had a negative return on equity of 65.23% and a negative net margin of 2,102.37%.The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.07 million. Equities analysts expect that Rallybio Corporation will post -1.34 earnings per share for the current year.

Hedge Funds Weigh In On Rallybio

A hedge fund recently raised its stake in Rallybio stock. Susquehanna International Group LLP boosted its stake in shares of Rallybio Corporation (NASDAQ:RLYB) by 485.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 136,294 shares of the company’s stock after purchasing an additional 113,031 shares during the quarter. Susquehanna International Group LLP owned approximately 0.32% of Rallybio worth $68,000 as of its most recent SEC filing. 90.34% of the stock is currently owned by hedge funds and other institutional investors.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.